Peginterferon alfa 2a

DRUG4 trials

Sponsors

Gilead Sciences, Xiamen Amoytop Biotech Co., Ltd., The Second Affiliated Hospital of Chongqing Medical University, Bristol-Myers Squibb

Conditions

Chronic Hepatitis BHCV InfectionHealthy SubjectsHepatitis C

Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Assessment of Ypeginterferon Alfa-2a in Healthy Subjects

CompletedNCT01343186

Xiamen Amoytop Biotech Co., Ltd.Healthy Subjects

Start: 2011-01-31End: 2011-11-30Updated: 2012-01-31

Phase 2

Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

CompletedNCT00743795

Gilead SciencesHCV Infection

Start: 2008-10-31End: 2013-09-30Updated: 2013-11-05

Phase 3

Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients

WithdrawnNCT01797848

Bristol-Myers SquibbHepatitis C

Start: 2014-06-30End: 2016-11-30Updated: 2013-11-25

Unknown Phase

A Study of Switch From Nucleotide to Peginterferon Alfa-2a in CHB Patients Achieving HBeAg Loss and HBV DNA <200IU/ml

The Second Affiliated Hospital of Chongqing Medical UniversityChronic Hepatitis B

Start: 2011-10-31End: 2016-12-31Target: 300Updated: 2011-11-03

Related Papers

[HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)-ide analog: new switch study].

PubMed2018-10-205 citations

HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study

Journal of Clinical and Translational Hepatology2018-03-17157 citations